Published: 25 December 2022
Author(s): Pierre Sabouret, Luigi Spadafora, David Fischman, Waqas Ullah, Michel Zeitouni, Martha Gulati, Salvatore De Rosa, Michael P. Savage, Juan Pablo Costabel, Maciej Banach, Giuseppe Biondi-Zoccai, Mattia Galli
Issue: April 2023
Section: Review Article

Since more than two decades, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is considered the gold standard for patients with acute coronary syndrome (ACS) as well as for those with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) [1]. The more potent P2Y12 inhibitors prasugrel and ticagrelor have shown to reduce ischemic events at the cost of increased bleeding compared with clopidogrel [2,3]. Therefore, a 12-month DAPT with potent P2Y12 inhibitors represents the standard-of-care after ACS and may be considered after PCI in CCS patients in specific high ischemic risk situations [4–6].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness